News & Events
First-in-class oncology medicines targeting human kinome.

Notice

May 26, 2025
Homepage renewal and opening
read more
Oct. 23, 2024
MBT-C101, a first-in-class, selective, and potent HSP90 chaperone mediated degrader of PI3Ka
read more
May 14, 2024
Certificate of Venture Enterprise
read more

Notice

May 26, 2025
Homepage renewal and opening
MBT's website has been newly created and opened.

Notice

May 14, 2024
Certificate of Venture Enterprise
On May 14, 2024, MBT has received a certificate of venture enterprise from the Korea Venture Business Association as a type of venture investment. (Issue No. 20240514010016)
Attachment

MBT_Certificate of Venture Enterprise.pdf

Notice

Oct. 23, 2024
MBT-C101, a first-in-class, selective, and potent HSP90 chaperone mediated degrader of PI3Ka
At the 2024 American Association for Cancer Research (AACR) Annual Meeting, MagicBullet Therapeutics presented preclinical data on their novel compound, MBT-C101.
Attachment

PI3K-MBT.pdf

1